Actualités

Amgen, Pfizer, Eli Lilly, Merck and Novo Nordisk are set to report Q2 results this week after a strong start for pharma earnings. Which names could beat forecasts?

A Mizuho healthcare analyst says merging two of pharma's biggest names could unlock a fortune, but the math only works if one brutal condition is met.

S&P 500 companies' second-quarter earnings growth has eased from a week ago as a sharp slowdown in p

J&J's oncology business posted strong Q2 growth as Darzalex, Erleada and newer cancer drugs boosted sales and advanced its long-term ambitions.

Stock Market Today: The Dow Jones index rallied 600 points Monday after Trump called off new U.S. strikes on Iran. Oil prices plunged.

The benchmark US stock measures were pointing higher before the opening bell Monday as President Don

Wall Street futures pointed moderately higher pre-bell Monday after President Donald Trump, over the

It is another big week on the earnings front with a lots of big name companies reporting. This week could make or break the market. This week we have SpaceX, Advanced Micro Devices, Palantir Technologies, Sandisk, Uber Technologies, McDonald’s, Caterpillar, Merck & Company, Disney, Shopify and Arista Networks all reporting in what shapes as a busy and pivotal week for stocks.

Global pharmaceutical company Merck (NYSE:MRK) will be announcing earnings results this Tuesday before market hours. Here’s what investors should know.

The monthly jobs report comes out Friday. Before that, Elon Musk’s SpaceX will post its first earnings report as a listed company. Also reporting: Walt Disney; tech companies Palantir and Advanced Micro Devices; ride-sharing firms Uber and Lyft; private-equity firms Apollo, Carlyle and TPG; and fast-food chains McDonald's and Wendy’s.

In another heavy earnings week, we’ll also see reports from McDonald’s, Disney, Uber, Devon Energy, and more.

Markets enter an earnings-dominated week with a huge concentration of corporate results spanning technology, industrials, healthcare, consumer discretionary, and entertainment sectors. This will provide a critical assessment of economic health and corporate fundamentals amid persistent uncertainty about technology sector valuations and AI infrastructure spending.

Merck (NYSE:MRK) has outlined a global access plan for its investigational once-monthly oral HIV prevention pill, alimatravir. The company is pursuing early voluntary licensing and regional manufacturing across 129 low and middle income countries ahead of Phase 3 completion. New public private partnerships and regulatory engagement aim to prepare health systems for a rapid rollout if the drug is approved. Merck enters this news cycle with its stock at $130.2 and a return of 22.3% year to...

Moderna's Q2 revenue tops estimates, but shares fall after its phase III norovirus vaccine study misses early success criteria.

Eli Lilly stock ran on a story that was public and dated long before the price moved, and reading it right still would not have put you ahead of every peer.

Here is a way to get paid a meaningful income now on your Eli Lilly shares, income you keep no matter what the stock does, in exchange for agreeing to sell at a price above today's if it climbs there.

The ETF industry keeps piling on the covered calls and derivative overlays, but three plain-vanilla dividend funds quietly pay over 4 percent by doing something almost radical: just owning stocks and collecting the cash.

While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.

Moderna posted a narrower per-share loss and higher revenue in its latest quarter, but shares were tumbling anyway. Moderna posted a loss of $1.97 a share, narrower than the loss of $2.01 Wall Street had anticipated, and slimmer than the per-share loss of $2.13 reported last year. The drugmaker reiterated its full-year guidance of 10% revenue growth, evenly split between U.S. and international sales.

This blockbuster class of drugs is shattering all sales records. Which stock will do better—Eli Lilly or Novo Nordisk?

MRK heads into Q2 earnings with acquisition costs, Keytruda strength and Gardasil challenges likely to shape results. Is the stock still worth holding?

Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Merck (MRK), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2026.

Merck stock has more than doubled over the past five years, and the latest Discounted Cash Flow (DCF) intrinsic value estimate now points to a sizeable gap versus the current share price, while the broader valuation checks suggest a more mixed picture. The roughly 102% total return over five years highlights how strongly the market has rewarded Merck over a full cycle and raises the bar for any further upside to be justified by fundamentals. Recent news around the FDA approval of the oral...

In the most recent trading session, Merck (MRK) closed at $130.36, indicating a -1.11% shift from the previous trading day.

The sticker shock on the pharma giant's shares fades once you look at what investors are paying for the earnings expected just two years from now.

MRNA is likely to face a key Q2 test as investors await results, FDA updates on mRNA-1010 and commercialization plans that could shape its post-COVID growth.

GILD heads into Q2 earnings with HIV franchise strength, rising Yeztugo expectations and oncology progress, even as Cell Therapy faces competitive pressure.

Zacks.com users have recently been watching Merck (MRK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Johnson & Johnson stock's oncology engine and its steady guidance raises were on the record quarters before the price moved.

One of the market's strongest health care performers barely moves with the index you already own, and that gap is the whole point.